Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

MIS Hematoma Evacuation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04466553
Recruitment Status : Withdrawn (The study did not begin.)
First Posted : July 10, 2020
Last Update Posted : December 16, 2021
Sponsor:
Information provided by (Responsible Party):
Lahey Clinic

Brief Summary:

The primary objective of this study is to determine the effectiveness of the NICO BrainPath™ hematoma evacuation system for patients between the ages of 18 and 80 years old with an intracerebral hematoma. Effectiveness will be defined as the ability to achieve either 70% reduction of intracranial hematoma or to achieve <15 ml residual hematoma volume following surgery.

Additionally, the study aims to compare the mortality and complication rate of patients who undergo minimally invasive, navigation guided endoport based evacuation of intracerebral hematoma with NICO BrainPath™ System as compared to non-operative, supportive standard of care.

The study is a prospective, non-randomized cohort study. 50 patients will be enrolled in Group A (NICO BrainPath™ system) and 50 patients will be matched retrospectively of similar diagnosis, undergoing standard of care from Epic). 50 patients will undergo minimally invasive, navigation guided endport based evacuation of intracerebral hematoma with NICO BrainPath™ System. The patient population receiving non-operative supportive care will be matched to the surgical patients based on age, gender, and location of hemorrhage.


Condition or disease Intervention/treatment
Intracranial Hematoma Device: NICO BrainPath™ System

Detailed Description:

Approximately 100 patients will participate in this study. Patients with significant intraparenchymal hemorrhage who are admitted under the neurology service in the Neurocritical Care and Medical ICU will be screened for eligibility.

A repeat CT scan 6 hours after stabilization to show that there has been no increase in size of the ICH will determine eligibility in the trial. Patients that meet eligibility criteria after this CT will be taken to the OR within 24-72 hours for a minimally invasive, navigation guided endoport based evacuation of the clot using the NICO BrainPath™ system.

At baseline, the Glasgow Coma Scale (GCS) and the Modified Rankin Score (mRS) will be captured, along with baseline demographics. The GCS and mRS will be recorded at 1-, 3, and 6-month post-operatively. A follow-up CT will be captured at 3 months. Mortality and adverse events will be reviewed at each timepoint.

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 6 Months
Official Title: MIS Hematoma Evacuation
Estimated Study Start Date : October 2021
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : August 2022

Group/Cohort Intervention/treatment
NICO BrainPath™ Patients

50 patients will be enrolled in Group A NICO BrainPath™ system.

The NICO BrainPath™ System has been proposed to reduce high morbidity and mortality associated with ICH through minimally invasive clot evacuation. Previous, single-center trials concluded evacuation of ICH using the BrainPath™ system as being safe and effective. Additionally, previous studies concluded that lesser ICH removal was correlated with mortality benefit and that the NICO BrainPath™ system approach was shown to be safe and effective with a high rate of clot evacuation and functional independence. This system warrants further research because of the need to optimize clinical outcome in these patients and to better define the role of hematoma evacuation in the care of these patients.

Device: NICO BrainPath™ System
Patients who are admitted under the neurology service in the Neurocritical Care and Medical ICU will be screened for participation in the trial by their treating physician. Once blood pressure has been stabilized and the best medical treatment has been determined, the patient will need to undergo a standard of care, repeat CT scan 6 hours after stabilization to show that there has been no increase in size of the ICH. Patients that meet eligibility criteria after this CT will be taken to the OR within 24-72 hours for a minimally invasive, navigation guided endoport based evacuation of the clot using the NICO BrainPath™ system.

Standard of Care
50 patients will be matched retrospectively of similar diagnosis, undergoing standard of care (e.g. no surgical intervention). These patients will be matched to the surgical patients based on age, gender, and location of hemorrhage.



Primary Outcome Measures :
  1. Effectiveness of the NICO BrainPath™ hematoma evacuation system [ Time Frame: immediately after the surgery. ]
    The primary objective of this study is to determine the effectiveness of the NICO BrainPath™ hematoma evacuation system for patients between the ages of 18 and 80 years old with an intracerebral hematoma. Effectiveness will be defined as the ability to achieve either 70% reduction of intracranial hematoma or to achieve <15 ml residual hematoma volume immediately after the surgery.


Secondary Outcome Measures :
  1. Comparison of mortality and complication rate. [ Time Frame: 6 months post-op ]
    Additionally, the study aims to compare the mortality and complication rate of patients who undergo minimally invasive, navigation guided endoport based evacuation of intracerebral hematoma with NICO BrainPath™ System as compared to non-operative, supportive standard of care until six months post-operative.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Male and females between the ages of 18-80 years old.
Criteria

Inclusion Criteria:

  1. 18 and 80 years of age, inclusive
  2. Spontaneous supratentorial, intracerebral hematoma ICH >30 ml measured by the ABC/2 method.
  3. Location of Hemorrhage: Lobar, Putaminal and/or Caudate
  4. A Glasgow Coma Scale (GCS) of 4 or greater
  5. Historical Modified Rankin Score (mRS) of 0 (no symptoms of neurological disability) or 1 (no significant disability despite symptoms, able to carry out usual duties and activities).

Exclusion Criteria:

  1. Pupils dilated and fixed
  2. Rapidly deteriorating patient (at the discretion of the surgeon)
  3. Primary Thalamic Bleed
  4. Intraventricular Blood (more than 50 % of either ventricle, visual estimate)
  5. ICH secondary to aneurysm
  6. Arteriovenous malformation (AVM)
  7. Tumor
  8. Moya-Moya
  9. Sinus thrombosis
  10. Platelet count <100,000, INR >1.4
  11. Known coagulopathy, on anticoagulants that cannot be reversed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04466553


Sponsors and Collaborators
Lahey Clinic
Investigators
Layout table for investigator information
Principal Investigator: Haran Ramachandran, MD Lahey Clinic
Study Chair: Zoher Ghogawala, MD Lahey Clinic
Layout table for additonal information
Responsible Party: Lahey Clinic
ClinicalTrials.gov Identifier: NCT04466553    
Other Study ID Numbers: 20203097
First Posted: July 10, 2020    Key Record Dates
Last Update Posted: December 16, 2021
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematoma
Hemorrhage
Pathologic Processes